JP2024516430A - 肺がん治療のためのピリミジニルアミノベンゼン - Google Patents

肺がん治療のためのピリミジニルアミノベンゼン Download PDF

Info

Publication number
JP2024516430A
JP2024516430A JP2023566849A JP2023566849A JP2024516430A JP 2024516430 A JP2024516430 A JP 2024516430A JP 2023566849 A JP2023566849 A JP 2023566849A JP 2023566849 A JP2023566849 A JP 2023566849A JP 2024516430 A JP2024516430 A JP 2024516430A
Authority
JP
Japan
Prior art keywords
amino
methyl
pyrimidin
dimethylamino
methoxy
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023566849A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024516430A5 (https=
Inventor
デュアン マオシェング
ユアン シュアイ
Original Assignee
スゾウ プヘ バイオファーマ シーオー．， エルティーディー
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by スゾウ プヘ バイオファーマ シーオー．， エルティーディー filed Critical スゾウ プヘ バイオファーマ シーオー．， エルティーディー
Publication of JP2024516430A publication Critical patent/JP2024516430A/ja
Publication of JP2024516430A5 publication Critical patent/JP2024516430A5/ja
Pending legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/506—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/04—Antineoplastic agents specific for metastasis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
JP2023566849A 2021-04-30 2022-05-02 肺がん治療のためのピリミジニルアミノベンゼン Pending JP2024516430A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CNPCT/CN2021/091463 2021-04-30
CN2021091463 2021-04-30
PCT/CN2022/090836 WO2022228578A1 (en) 2021-04-30 2022-05-02 Pyrimidinylaminobenzenes for lung cancer treatment

Publications (2)

Publication Number Publication Date
JP2024516430A true JP2024516430A (ja) 2024-04-15
JP2024516430A5 JP2024516430A5 (https=) 2025-06-05

Family

ID=83847794

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023566849A Pending JP2024516430A (ja) 2021-04-30 2022-05-02 肺がん治療のためのピリミジニルアミノベンゼン

Country Status (6)

Country Link
US (1) US20240226101A1 (https=)
EP (1) EP4330256A4 (https=)
JP (1) JP2024516430A (https=)
KR (1) KR20240027583A (https=)
CN (1) CN117561254A (https=)
WO (1) WO2022228578A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024094064A1 (en) * 2022-11-02 2024-05-10 Suzhou Puhe Biopharma Co., Ltd Pyrimidinylaminobenzenes for treating lung cancer with distant metastasis
CN116098873A (zh) * 2023-03-08 2023-05-12 苏州浦合医药科技有限公司 一种药物制剂及其制备方法

Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104761544A (zh) * 2014-01-03 2015-07-08 南京波尔泰药业科技有限公司 Egfr酪氨酸激酶的临床重要突变体的选择性抑制剂
CN106279160A (zh) * 2016-03-18 2017-01-04 海南越康生物医药有限公司 N‑苯基‑2‑氨基嘧啶类化合物制备方法和用途
JP2017533266A (ja) * 2014-11-05 2017-11-09 インベンティスバイオ シャンハイ リミテッド ピリミジン又はピリジン系化合物、それらの製造方法及び医薬使用
WO2018234556A1 (en) * 2017-06-23 2018-12-27 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS OF PREVENTING OR TREATING CANCER RESISTANCE TO EGFR INHIBITION
JP2019516766A (ja) * 2016-05-26 2019-06-20 ゼノ ロイアルティー アンド マイルストーンズ リミテッド ライアビリティー カンパニー Ｅｇｆｒ阻害剤化合物
JP2020525420A (ja) * 2017-06-13 2020-08-27 ベイジン アダマドル バイオテクノロジー リミテッド ライアビリティ カンパニー アミノピリミジン化合物、その調製方法、およびその使用
JP2020526499A (ja) * 2017-07-05 2020-08-31 シーエス ファーマテック リミテッド Ｅｇｆｒチロシンキナーゼの臨床上重要な突然変異体の選択的阻害剤
JP2020526593A (ja) * 2017-07-19 2020-08-31 海南越康生物医薬有限公司 Ｎ−フェニル−２−アミノピリミジン類化合物の結晶形、塩形態及びその製造方法
WO2020200158A1 (zh) * 2019-03-29 2020-10-08 深圳福沃药业有限公司 用于治疗癌症的氮杂芳环酰胺衍生物

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP3585389A4 (en) * 2017-02-22 2020-12-23 G1 Therapeutics, Inc. EGFR-CAUSED CANCER TREATMENT WITH LESS SIDE EFFECTS
JP2021513517A (ja) * 2018-02-12 2021-05-27 アストラゼネカ・アクチエボラーグＡｓｔｒａｚｅｎｅｃａ Ａｋｔｉｅｂｏｌａｇ 非小細胞肺がんの治療に使用するためのオシメルチニブ
CN111588710B (zh) * 2019-02-21 2023-06-20 浙江大学 一种针对egfr耐药突变c797s的联用药物及用途

Patent Citations (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104761544A (zh) * 2014-01-03 2015-07-08 南京波尔泰药业科技有限公司 Egfr酪氨酸激酶的临床重要突变体的选择性抑制剂
JP2017533266A (ja) * 2014-11-05 2017-11-09 インベンティスバイオ シャンハイ リミテッド ピリミジン又はピリジン系化合物、それらの製造方法及び医薬使用
CN106279160A (zh) * 2016-03-18 2017-01-04 海南越康生物医药有限公司 N‑苯基‑2‑氨基嘧啶类化合物制备方法和用途
JP2019516766A (ja) * 2016-05-26 2019-06-20 ゼノ ロイアルティー アンド マイルストーンズ リミテッド ライアビリティー カンパニー Ｅｇｆｒ阻害剤化合物
JP2020525420A (ja) * 2017-06-13 2020-08-27 ベイジン アダマドル バイオテクノロジー リミテッド ライアビリティ カンパニー アミノピリミジン化合物、その調製方法、およびその使用
WO2018234556A1 (en) * 2017-06-23 2018-12-27 INSERM (Institut National de la Santé et de la Recherche Médicale) METHODS OF PREVENTING OR TREATING CANCER RESISTANCE TO EGFR INHIBITION
JP2020526499A (ja) * 2017-07-05 2020-08-31 シーエス ファーマテック リミテッド Ｅｇｆｒチロシンキナーゼの臨床上重要な突然変異体の選択的阻害剤
JP2020526593A (ja) * 2017-07-19 2020-08-31 海南越康生物医薬有限公司 Ｎ−フェニル−２−アミノピリミジン類化合物の結晶形、塩形態及びその製造方法
WO2020200158A1 (zh) * 2019-03-29 2020-10-08 深圳福沃药业有限公司 用于治疗癌症的氮杂芳环酰胺衍生物

Also Published As

Publication number Publication date
WO2022228578A1 (en) 2022-11-03
KR20240027583A (ko) 2024-03-04
EP4330256A1 (en) 2024-03-06
EP4330256A4 (en) 2025-03-05
US20240226101A1 (en) 2024-07-11
CN117561254A (zh) 2024-02-13

Similar Documents

Publication Publication Date Title
US20240190883A1 (en) Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
US20250177334A1 (en) Pharmaceutical Compositions Comprising Phenylsulfonamides, and Their Therapeutic Applications
WO2022212611A1 (en) Kras protein degraders, pharmaceutical compositions thereof, and their therapeutic applications
US20260007685A1 (en) Anti-apoptotic bcl-2 family protein degraders, pharmaceutical compositions, and therapeutic applications
JP2024516430A (ja) 肺がん治療のためのピリミジニルアミノベンゼン
ES2928666T3 (es) Piridinetionas, sus composiciones farmacéuticas y su uso terapéutico para el tratamiento de enfermedades proliferativas, inflamatorias, neurodegenerativas o inmunomediadas
US20240116845A1 (en) Indene compounds, pharmaceutical compositions thereof, and their therapeutic applications
AU2023381655A1 (en) Indene compounds, pharmaceutical compositions thereof, and their therapeutic applications
AU2011261501B2 (en) Methods of treating hematologic malignancies using 6-cyclohexyl-1-hydroxy-4-methyl-2(1H)-pyridone
TW202406904A (zh) Ｃｄｋ抑制劑、醫藥組成物及其治療應用
WO2024094064A1 (en) Pyrimidinylaminobenzenes for treating lung cancer with distant metastasis
WO2024104422A1 (en) Phosphorus-containing compounds for treating inflammatory bowel diesease
US20240197713A1 (en) Lfa-1 antagonists for treating inflammatory bowel diesease
WO2023023474A1 (en) Tr-beta modulators, pharmaceutical compositions, and therapeutic applications
WO2026080552A1 (en) Deoxycytidine kinase inhibitors for treating inflammatory bowel diseases
HK40120126A (zh) Cdk抑制剂、药物组合物及其治疗应用
WO2023143476A1 (en) Deuterated rock inhibitors, pharmaceutical compositions, and therapeutic applications
CN118891036A (zh) 双环醌、药物组合物和治疗应用
CA3042055C (en) Nitrite salts of 1,1-dimethylbiguanide, pharmaceutical compositions, and methods of use
CN120590341A (zh) 脂质化合物、脂质纳米颗粒和药物组合物
JP2025541836A (ja) ホスホロアミダートモノサッカライド、医薬組成物、並びに診断的及び治療的応用

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250519

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250519

A917 Reason for reinstatement of right to file examination request

Free format text: JAPANESE INTERMEDIATE CODE: A917

Effective date: 20250519

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20250520

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20250519

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20260324

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20260327